Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer
Status:
Active, not recruiting
Trial end date:
2022-02-02
Target enrollment:
Participant gender:
Summary
This is a phase II, open-label, single arm, single-stage study. Both, chemo-sensitive and
chemo-resistant patients will be enrolled and treated with 4 cycles of combination of
Guadecitabine and carboplatin
Phase:
Phase 2
Details
Lead Sponsor:
Shadia Jalal, MD
Collaborators:
Astex Pharmaceuticals Astex Pharmaceuticals, Inc. Indiana University School of Medicine